SlideShare a Scribd company logo
elcc-congress.org
LUNG CANCER: 10-YEAR SURVIVAL
#358
Kshivets Oleg
Surgery Department, Roshal Hospital, Moscow, Russia
No disclosures
e-mail: okshivets@yahoo.com
EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021
DECLARATION OF INTERESTS
Oleg Kshivets
No disclosures
EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021
LUNG CANCER: 10-YEAR SURVIVAL #358
Oleg Kshivets, MD, PhD
Surgery Department, Roshal Hospital, Roshal, Moscow, Russia
OBJECTIVE: 10-Year survial (10YS) after radical surgery for non-small cell lung cancer (LC) patients (LCP) (T1-4N0-2M0) was analyzed.
METHODS: We analyzed data of 768 consecutive LCP (age=57.6±8.3 years; tumor size=4.1±2.4 cm) radically operated (R0) and monitored in 1985-2021
(m=660, f=108; upper lobectomies=277, lower lobectomies=177, middle lobectomies=18, bilobectomies=42, pneumonectomies=254, mediastinal lymph node
dissection=768; combined procedures with resection of trachea, carina, atrium, aorta, VCS, vena azygos, pericardium, liver, diaphragm, ribs, esophagus=193;
only surgery-S=618, adjuvant chemoimmunoradiotherapy-AT=150: CAV/gemzar + cisplatin + thymalin/taktivin + radiotherapy 45-50Gy; T1=320, T2=255, T3=133,
T4=60; N0=516, N1=131, N2=121, M0=768; G1=194, G2=243, G3=331; squamous=417, adenocarcinoma=301, large cell=50; early LC=214, invasive LC=554; right
LC=412, left LC=356; central=290; peripheral=478. Variables selected for 10YS study were input levels of 45 blood parameters, sex, age, TNMG, cell type, tumor
size. Survival curves were estimated by the Kaplan-Meier method. Differences in curves between groups of LCP were evaluated using a log-rank test.
Multivariate Cox modeling, discriminant analysis, clustering, SEPATH, Monte Carlo, bootstrap and neural networks computing were used to determine any
significant dependence.
RESULTS: Overall life span (LS) was 2244.9±1750.3 days and cumulative 5-year survival (5YS) reached 72.9%, 10 years – 64.3%, 20 yers – 43.1%. 502 LCP
lived more than 5 years (LS=3128.7±1536.8 days), 145 LCP – more than 10 years (LS=5068.5±1513.2 days).199 LCP died because of LC (LS=562.7±374.5 days).
AT significantly improved 10YS (52.4% vs. 27.7%) (P=0.00002 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 10YS of LCP significantly
depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells
subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time, weight, color index (P=0.000-0.039).
Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 10YS and PT early-invasive LC (rank=1),
thrombocytes/CC (rank=2), PT N0—N12(rank=3), segmented neutrophils/CC (4), healthy cells/CC (5), lymphocytes/CC (6), erythrocytes/CC (7), stick
neutrophils/CC (8), eosinophils/CC (9), leucocytes/CC (10), monocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under
ROC curve=1.0; error=0.0).
CONCLUSIONS: 10-Year survival of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4)
blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) anthropometric data; 10) surgery type; 11) tumor localization.
Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of
complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant
chemoimmunoradiotherapy for LCP with unfavorable prognosis.
EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021
DATA:
Males…………………………………….…………………………..…….660
Females…….......................................................................................108
Age=57.6±8.3 years Tumor Size=4.1±2.4 cm
Only Surgery.…..................................................................................618
Adjuvant Chemoimmunoradiotherapy (CAV/gemzar + cisplatin +
thymalin/taktivin, 5-6 cycles+ Radiotherapy 45-50Gy)...................150
EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021
RADICAL PROCEDURES (R0):
Upper Lobectomies …………………….………………………………...277
Lower Lobectomies ……………..........................................................177
Middle Lobectomies………………….…..………………………………..18
Bilobectomies……………………………………..…………………….…..42
Pneumonectomies…………………………………………………..…....254
Combined Procedures with Resection of Carina, Trachea, Atrium,
Aorta, Liver, Vena Cava Superior, Vena Azygos, Diaphragm,
Pericardium, Ribs, Esophagus (R0)…………………………………...193
Mediastinal Lymph Node Dissection.……………………………….…768
EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021
SURVIVAL RATE:
5-Year Survivors…………......................................................502 (65.4%)
10-Year Survivors……………………………………................145 (18.9%)
Losses……………………………………………………………..199 (25.9%)
General Life Span=2244.9±1750.3 days
For 5-Year Survivors=3128.7±1536.8 days
For 10-Year Survivors=5068.5±1513.2 days
For Losses=562.7±374.5 days
Cumulative 5-Year Survival……..……….........................................72.9%
Cumulative 10-Year Survival……..…...……………………………...64.3%
Cumulative 20-Year Survival………………………………………....43.1%
EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021
GENERAL LUNG CANCER PATIENTS SURVIVAL AFTER COMPLETE
LOBECTOMIES/PNEUMONECTOMIES (KAPLAN-MEIER) (N=768):
Survival Function
5-Year Survival=72.9%; 10-Year survival=64.3%; 20-Year Survival=43.1%;
n=768; T1-4N0-2M0
Complete Censored
-5 0 5 10 15 20 25 30
Years after Lobectomies/Pneumonectomies
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Cumulative
Proportion
Surviving
EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021
RESULTS OF UNIVARIATE ANALYSIS OF PHASE TRANSITION EARLY—INVASIVE
CANCER IN PREDICTION OF LUNG CANCER PATIENTS SURVIVAL (N=768):
Cumulative Proportion Surviving (Kaplan-Meier)
10-Year Survival of Early Lung Cancer Patients=93.9%;
10-Year Surival of Invasive Lung Cancer Patients=51.8%;
P=0.0000 by Log Rank Test
Complete Censored
0 5 10 15 20 25 30 35
Years after Lobectomies/Pneumonectomies
-0.2
0.0
0.2
0.4
0.6
0.8
1.0
Cumulative
Proportion
Surviving
Invasive Lung Cancer, n=554
Early Lung Cancer, n=214
EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021
RESULTS OF UNIVARIATE ANALYSIS OF PHASE TRANSITION N0—N1-2 IN
PREDICTION OF LUNG CANCER PATIENTS SURVIVAL (N=768):
Cumulative Proportion Surviving (Kaplan-Meier)
10-Year Survival of Lung Cancer Patients with N0=78.3%;
10-Year Survival of Lung Cancer Patients with N1-2=35.2%;
P=0.0000 by Log Rank Test
Complete Censored
0 5 10 15 20 25 30 35
Years After Lobectomies/Pneumonectomies
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Cumulative
Proportion
Surviving
Lung Cancer with N1-2, n=252
Lung Cancer with N0=516
EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021
RESULTS OF UNIVARIATE ANALYSIS OF ADJUVANT CHEMOIMMUNORADIOTHERAPY IN
PREDICTION OF LUNG CANCER PATIENTS SURVIVAL WITH N1-2 (N=252):
Cumulative Proportion Surviving (Kaplan-Meier)
10-Year Survival of LCP after AT=52.4%;
10-Year Survival of LCP after Surgery=27.7%;
P=0.00002 by Log Rank Test
Complete Censored
0 5 10 15 20 25 30
Years after Lobectomies/Pneumonectomies
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Cumulative
Proportion
Surviving
Only Surgery, n=164
Adjuvant Chemoimmunoradiotherapy, n=88
EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021
Cumulative Proportion Surviving (Kaplan-Meier)
10-Year Survival after Lobectomies=72%;
10-Year Survival after Pneumonectomies=46.9%;
P=0.00002 by Log Rank Test
Complete Censored
0 5 10 15 20 25 30 35
Years after Lobectomies/Pneumonectomies
-0.1
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Cumulative
Proportion
Surviving
Pneumonectomies, n=254
Lobectomies, n=514
RESULTS OF UNIVARIATE ANALYSIS OF TYPE OF PROCEDURES IN
PREDICTION OF LUNG CANCER PATIENTS SURVIVAL (N=768):
EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021
RESULTS OF UNIVARIATE ANALYSIS OF GENDER IN PREDICTION
OF LUNG CANCER PATIENTS SURVIVAL (N=768):
Cumulative Proportion Surviving (Kaplan-Meier)
10-Year Survival of Female LCP=73.4%;
10-Year Survival of Male LCP=63.4%;
P=0.0289 by Log Rank Test
Complete Censored
0 5 10 15 20 25 30 35
Years after Lobectomies/Pneumonectomies
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Cumulative
Proportion
Surviving
male, n=660
female, n=108
EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021
RESULTS OF COX REGRESSION MODELING IN PREDICTION OF LUNG CANCER
PATIENTS SURVIVAL AFTER COMPLETE LOBECTOMIES/PNEUMONECTOMIES (N=768):
Cox Proportional Hazards Results,
LCP T1-4N0-2M0, n=768
Parameter
Estimate
Standard
Error
Chi-square P value
Thrombocytes/Cancer Cells -0.00550 0.001579 12.14276 0.000493
Healthy Cells/Cancer Cells 0.07391 0.024958 8.77037 0.003062
Adjuvant Chemoimmunoradiotherapy -1.13036 0.201727 31.39806 0.000000
Phase Transition N0---N12 1.12121 0.144416 60.27584 0.000000
Phase Transition Early-Invasive Cancer -1.47130 0.341717 18.53830 0.000017
Histology 0.35066 0.084684 17.14621 0.000035
G1-3 0.36443 0.087580 17.31503 0.000032
Color Index -2.18363 0.917025 5.67018 0.017256
Glucose -0.32526 0.078234 17.28559 0.000032
Prothrombin Index 0.03372 0.006854 24.20847 0.000001
Bilirubin 0.05124 0.018274 7.86319 0.005045
Recalcification Time -0.00444 0.001711 6.73236 0.009468
Heparin Tolerance 0.00392 0.000662 35.06287 0.000000
Thrombocytes (tot) 0.00172 0.000341 25.43339 0.000000
Monocytes -0.05039 0.024421 4.25828 0.039059
Weight -0.03451 0.008725 15.64460 0.000076
EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021
RESULTS OF NEURAL NETWORKS COMPUTING IN PREDICTION OF LUNG CANCER
PATIENTS SURVIVAL AFTER COMPLETE LOBECTOMIES/PNEUMONECTOMIES (N=701):
Neural Networks: n=701;
Baseline Error=0.000;
Area under ROC Curve=1.000;
Correct Classification Rate=100%
Rank Sensitivity
Phase Transition Early--Invasive Cancer 1 11646
Thrombocytes/Cancer Cells 2 7184
Phase Transition N0--N12
Segmented Neutrophils/Cancer Cells
Healthy Cells/Cancer Cells
Lymphocytes/Cancer Cells
Erythrocytes/Cancer Cells
Stick Neutrophils/Cancer Cells
Eosinophils/Cancer Cells
Leucocytes/Cancer Cells
Monocytes/Cancer Cells
3
4
5
6
7
8
9
10
11
6656
4154
4407
3993
3370
2963
2224
1566
1206
EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021
RESULTS OF BOOTSTRAP SIMULATION IN PREDICTION OF LUNG CANCER PATIENTS
SURVIVAL AFTER LOBECTOMIES/PNEUMONECTOMIES (N=701):
Bootstrap Simulation n=701
Significant Factors
(Number of Samples=3333)
Rank Kendall’Tau-A P<
Lymphocytes/Cancer Cells 1 0.269 0.000
Leucocytes/Cancer Cells 2 0.223 0.000
Healthy Cells/Cancer Cells 3 0.211 0.000
Erythrocytes/Cancer Cells 4 0.193 0.000
Thrombocytes/Cancer Cells 5 0.192 0.000
Lymphocytes (tot) 6 0.183 0.000
Segmented Neutrophils/Cancer Cells 7 0.173 0.000
Tumor Size 8 -0.118 0.000
Monocytes/Cancer Cells 9 0.111 0.000
PT Early---Invasive Cancer 10 0.107 0.000
Lymphocytes (%) 11 0.105 0.000
Segmented Neutrophils (%) 12 -0.102 0.000
Lymphocytes (abs) 13 0.096 0.000
Prothrombin Index 14 -0.094 0.001
T1-4 15 -0.094 0.001
PT N0---N12 16 -0.092 0.001
Procedures Type 17 0.087 0.01
Histology 18 0.076 0.01
Stick Neutrophils/Cancer Cells 19 0.073 0.01
Eosinophils/Cancer Cells 20 0.067 0.05
Age 21 -0.067 0.05
Fibrinogen 22 -0.052 0.05
EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021
RESULTS OF KOHONEN SELF-ORGANIZING NEURAL NETWORKS COMPUTING IN PREDICTION OF
LUNG CANCER PATIENTS SURVIVAL AFTER LOBECTOMIES/PNEUMONECTOMIES (N=701):
EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021
LUNG CANCER DYNAMICS:
EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021
PROGNOSTIC EQUATION MODELS OF LUNG CANCER PATIENTS SURVIVAL
AFTER LOBECTOMIES/PNEUMONECTOMIES (N=701):
EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021
PROGNOSTIC EQUATION MODELS OF LUNG CANCER PATIENTS SURVIVAL
AFTER LOBECTOMIES/PNEUMONECTOMIES (N=701):
EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021
PROGNOSTIC SEPATH-MODEL OF LUNG CANCER PATIENTS SURVIVAL
AFTER LOBECTOMIES/PNEUMONECTOMIES (N=701):
EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021
Conclusion:
10-Year survival of LCP after radical procedures significantly depended on:
1) phase transition early-invasive cancer;
2) phase transition N0--N12;
3) cell ratio factors;
4) blood cell circuit;
5) biochemical factors;
6) hemostasis system;
7) adjuvant chemoimmunoradiotherapy;
8) lung cancer characteristics;
9) anthropometric data;
10) surgery type;
11) tumor localization.
EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021
Conclusion:
Optimal diagnosis and treatment strategies for lung cancer are:
1) screening and early detection;
2) availability of experienced thoracic surgeons because of complexity of
radical procedures;
3) aggressive en block surgery and adequate lymph node dissection for
completeness;
4) precise prediction;
5) adjuvant chemoimmunoradiotherapy for lung cancer patients with
unfavorable prognosis.
elcc-congress.org
Address: Oleg Kshivets, M.D., Ph.D.
Consultant Thoracic, Abdominal, General Surgeon
& Surgical Oncologist
e-mail: okshivets@yahoo.com
skype: okshivets
http: //www.ctsnet.org/home/okshivets

More Related Content

What's hot

Kshivets IASLC_Vienna2016
Kshivets IASLC_Vienna2016Kshivets IASLC_Vienna2016
Kshivets IASLC_Vienna2016
Oleg Kshivets
 
Kshivets aats new_york2019
Kshivets aats new_york2019Kshivets aats new_york2019
Kshivets aats new_york2019
Oleg Kshivets
 
Kshivets sso2013
Kshivets sso2013Kshivets sso2013
Kshivets sso2013
Oleg Kshivets
 
Kshivets barcelona2019
Kshivets barcelona2019Kshivets barcelona2019
Kshivets barcelona2019
Oleg Kshivets
 
Kshivets eacts milan2018
Kshivets eacts milan2018Kshivets eacts milan2018
Kshivets eacts milan2018
Oleg Kshivets
 
PRECISE EARLY DETECTION OF LUNG CANCER AND IMMUNE CIRCUIT
PRECISE EARLY DETECTION OF LUNG  CANCER AND IMMUNE CIRCUITPRECISE EARLY DETECTION OF LUNG  CANCER AND IMMUNE CIRCUIT
PRECISE EARLY DETECTION OF LUNG CANCER AND IMMUNE CIRCUIT
Oleg Kshivets
 
Kshivets ASCO Chicago2020
Kshivets ASCO Chicago2020Kshivets ASCO Chicago2020
Kshivets ASCO Chicago2020
Oleg Kshivets
 
Kshivets O. Lung Cancer Surgery: Prognosis
Kshivets O. Lung Cancer Surgery: PrognosisKshivets O. Lung Cancer Surgery: Prognosis
Kshivets O. Lung Cancer Surgery: Prognosis
Oleg Kshivets
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer Surgery
Oleg Kshivets
 
Kshivets wscts2018 ljubljana
Kshivets wscts2018 ljubljanaKshivets wscts2018 ljubljana
Kshivets wscts2018 ljubljana
Oleg Kshivets
 
Kshivets O. Lung Cancer: Early Detection and Diagnosis
Kshivets O. Lung Cancer: Early Detection and Diagnosis Kshivets O. Lung Cancer: Early Detection and Diagnosis
Kshivets O. Lung Cancer: Early Detection and Diagnosis
Oleg Kshivets
 
Kshivets chicago2016
Kshivets chicago2016Kshivets chicago2016
Kshivets chicago2016
Oleg Kshivets
 
Kshivets wscts2015
Kshivets wscts2015Kshivets wscts2015
Kshivets wscts2015
Oleg Kshivets
 
Kshivets iaslc denver2015
Kshivets iaslc denver2015Kshivets iaslc denver2015
Kshivets iaslc denver2015
Oleg Kshivets
 
Kshivets yokohama iaslc2017
Kshivets yokohama iaslc2017Kshivets yokohama iaslc2017
Kshivets yokohama iaslc2017
Oleg Kshivets
 
Kshivets O. Esophageal & Cardioesophageal Cancer Surgery
Kshivets O.  Esophageal & Cardioesophageal Cancer SurgeryKshivets O.  Esophageal & Cardioesophageal Cancer Surgery
Kshivets O. Esophageal & Cardioesophageal Cancer Surgery
Oleg Kshivets
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer Surgery
Oleg Kshivets
 
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
Oleg Kshivets
 
Kshivets esmo2021
Kshivets esmo2021Kshivets esmo2021
Kshivets esmo2021
Oleg Kshivets
 
Kshivets O. Cardioesophageal Cancer Surgery
Kshivets O. Cardioesophageal Cancer SurgeryKshivets O. Cardioesophageal Cancer Surgery
Kshivets O. Cardioesophageal Cancer Surgery
Oleg Kshivets
 

What's hot (20)

Kshivets IASLC_Vienna2016
Kshivets IASLC_Vienna2016Kshivets IASLC_Vienna2016
Kshivets IASLC_Vienna2016
 
Kshivets aats new_york2019
Kshivets aats new_york2019Kshivets aats new_york2019
Kshivets aats new_york2019
 
Kshivets sso2013
Kshivets sso2013Kshivets sso2013
Kshivets sso2013
 
Kshivets barcelona2019
Kshivets barcelona2019Kshivets barcelona2019
Kshivets barcelona2019
 
Kshivets eacts milan2018
Kshivets eacts milan2018Kshivets eacts milan2018
Kshivets eacts milan2018
 
PRECISE EARLY DETECTION OF LUNG CANCER AND IMMUNE CIRCUIT
PRECISE EARLY DETECTION OF LUNG  CANCER AND IMMUNE CIRCUITPRECISE EARLY DETECTION OF LUNG  CANCER AND IMMUNE CIRCUIT
PRECISE EARLY DETECTION OF LUNG CANCER AND IMMUNE CIRCUIT
 
Kshivets ASCO Chicago2020
Kshivets ASCO Chicago2020Kshivets ASCO Chicago2020
Kshivets ASCO Chicago2020
 
Kshivets O. Lung Cancer Surgery: Prognosis
Kshivets O. Lung Cancer Surgery: PrognosisKshivets O. Lung Cancer Surgery: Prognosis
Kshivets O. Lung Cancer Surgery: Prognosis
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer Surgery
 
Kshivets wscts2018 ljubljana
Kshivets wscts2018 ljubljanaKshivets wscts2018 ljubljana
Kshivets wscts2018 ljubljana
 
Kshivets O. Lung Cancer: Early Detection and Diagnosis
Kshivets O. Lung Cancer: Early Detection and Diagnosis Kshivets O. Lung Cancer: Early Detection and Diagnosis
Kshivets O. Lung Cancer: Early Detection and Diagnosis
 
Kshivets chicago2016
Kshivets chicago2016Kshivets chicago2016
Kshivets chicago2016
 
Kshivets wscts2015
Kshivets wscts2015Kshivets wscts2015
Kshivets wscts2015
 
Kshivets iaslc denver2015
Kshivets iaslc denver2015Kshivets iaslc denver2015
Kshivets iaslc denver2015
 
Kshivets yokohama iaslc2017
Kshivets yokohama iaslc2017Kshivets yokohama iaslc2017
Kshivets yokohama iaslc2017
 
Kshivets O. Esophageal & Cardioesophageal Cancer Surgery
Kshivets O.  Esophageal & Cardioesophageal Cancer SurgeryKshivets O.  Esophageal & Cardioesophageal Cancer Surgery
Kshivets O. Esophageal & Cardioesophageal Cancer Surgery
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer Surgery
 
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
 
Kshivets esmo2021
Kshivets esmo2021Kshivets esmo2021
Kshivets esmo2021
 
Kshivets O. Cardioesophageal Cancer Surgery
Kshivets O. Cardioesophageal Cancer SurgeryKshivets O. Cardioesophageal Cancer Surgery
Kshivets O. Cardioesophageal Cancer Surgery
 

Similar to Lung Cancer: 10-Year Survival

Kshivets ny2021aats
Kshivets ny2021aatsKshivets ny2021aats
Kshivets ny2021aats
Oleg Kshivets
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Oleg Kshivets
 
Kshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdfKshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdf
Oleg Kshivets
 
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Oleg Kshivets
 
Esophageal Cancer: Artificial Intelligence, Synergetics, Complex System Analy...
Esophageal Cancer: Artificial Intelligence, Synergetics, Complex System Analy...Esophageal Cancer: Artificial Intelligence, Synergetics, Complex System Analy...
Esophageal Cancer: Artificial Intelligence, Synergetics, Complex System Analy...
Oleg Kshivets
 
Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...
Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...
Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...
Oleg Kshivets
 
Kshivets O. Local Advanced Lung Cancer Surgery
Kshivets O. Local Advanced Lung Cancer Surgery Kshivets O. Local Advanced Lung Cancer Surgery
Kshivets O. Local Advanced Lung Cancer Surgery
Oleg Kshivets
 
Kshivets O. Lung Cancer Surgery: Synergetics and Prediction
Kshivets O. Lung Cancer Surgery: Synergetics and PredictionKshivets O. Lung Cancer Surgery: Synergetics and Prediction
Kshivets O. Lung Cancer Surgery: Synergetics and Prediction
Oleg Kshivets
 
Kshivets ASCVTS Moscow2018
Kshivets ASCVTS Moscow2018Kshivets ASCVTS Moscow2018
Kshivets ASCVTS Moscow2018
Oleg Kshivets
 
Kshivets lc10 ys_wjarr
Kshivets lc10 ys_wjarrKshivets lc10 ys_wjarr
Kshivets lc10 ys_wjarr
Oleg Kshivets
 
Kshivets_SPB_WSCTS2022Eso.pdf
Kshivets_SPB_WSCTS2022Eso.pdfKshivets_SPB_WSCTS2022Eso.pdf
Kshivets_SPB_WSCTS2022Eso.pdf
Oleg Kshivets
 
Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction      Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction
Oleg Kshivets
 
Kshivets barcelona2020
Kshivets barcelona2020Kshivets barcelona2020
Kshivets barcelona2020
Oleg Kshivets
 
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...
Oleg Kshivets
 
KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdf
Oleg Kshivets
 
KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdf
Oleg Kshivets
 
KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdf
Oleg Kshivets
 
Kshivets milan2014
Kshivets milan2014Kshivets milan2014
Kshivets milan2014
Oleg Kshivets
 
Kshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdfKshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdf
Oleg Kshivets
 
Kshivets O. Esophageal and Cardioesophageal Cancer Surgery
Kshivets O. Esophageal and Cardioesophageal Cancer SurgeryKshivets O. Esophageal and Cardioesophageal Cancer Surgery
Kshivets O. Esophageal and Cardioesophageal Cancer Surgery
Oleg Kshivets
 

Similar to Lung Cancer: 10-Year Survival (20)

Kshivets ny2021aats
Kshivets ny2021aatsKshivets ny2021aats
Kshivets ny2021aats
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
 
Kshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdfKshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdf
 
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
 
Esophageal Cancer: Artificial Intelligence, Synergetics, Complex System Analy...
Esophageal Cancer: Artificial Intelligence, Synergetics, Complex System Analy...Esophageal Cancer: Artificial Intelligence, Synergetics, Complex System Analy...
Esophageal Cancer: Artificial Intelligence, Synergetics, Complex System Analy...
 
Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...
Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...
Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...
 
Kshivets O. Local Advanced Lung Cancer Surgery
Kshivets O. Local Advanced Lung Cancer Surgery Kshivets O. Local Advanced Lung Cancer Surgery
Kshivets O. Local Advanced Lung Cancer Surgery
 
Kshivets O. Lung Cancer Surgery: Synergetics and Prediction
Kshivets O. Lung Cancer Surgery: Synergetics and PredictionKshivets O. Lung Cancer Surgery: Synergetics and Prediction
Kshivets O. Lung Cancer Surgery: Synergetics and Prediction
 
Kshivets ASCVTS Moscow2018
Kshivets ASCVTS Moscow2018Kshivets ASCVTS Moscow2018
Kshivets ASCVTS Moscow2018
 
Kshivets lc10 ys_wjarr
Kshivets lc10 ys_wjarrKshivets lc10 ys_wjarr
Kshivets lc10 ys_wjarr
 
Kshivets_SPB_WSCTS2022Eso.pdf
Kshivets_SPB_WSCTS2022Eso.pdfKshivets_SPB_WSCTS2022Eso.pdf
Kshivets_SPB_WSCTS2022Eso.pdf
 
Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction      Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction
 
Kshivets barcelona2020
Kshivets barcelona2020Kshivets barcelona2020
Kshivets barcelona2020
 
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...
 
KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdf
 
KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdf
 
KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdf
 
Kshivets milan2014
Kshivets milan2014Kshivets milan2014
Kshivets milan2014
 
Kshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdfKshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdf
 
Kshivets O. Esophageal and Cardioesophageal Cancer Surgery
Kshivets O. Esophageal and Cardioesophageal Cancer SurgeryKshivets O. Esophageal and Cardioesophageal Cancer Surgery
Kshivets O. Esophageal and Cardioesophageal Cancer Surgery
 

More from Oleg Kshivets

Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Oleg Kshivets
 
Kshivets Oleg Optimization of Management for Esophageal Cancer Patients (T1-...
Kshivets Oleg  Optimization of Management for Esophageal Cancer Patients (T1-...Kshivets Oleg  Optimization of Management for Esophageal Cancer Patients (T1-...
Kshivets Oleg Optimization of Management for Esophageal Cancer Patients (T1-...
Oleg Kshivets
 
Kshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdfKshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdf
Oleg Kshivets
 
Kshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdfKshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdf
Oleg Kshivets
 
Kshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdfKshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdf
Oleg Kshivets
 
Lung Cancer: Precise Prediction
Lung Cancer: Precise PredictionLung Cancer: Precise Prediction
Lung Cancer: Precise Prediction
Oleg Kshivets
 
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...
Oleg Kshivets
 
• Gastric cancer prognosis and cell ratio factors
•	Gastric cancer prognosis and cell ratio factors           •	Gastric cancer prognosis and cell ratio factors
• Gastric cancer prognosis and cell ratio factors
Oleg Kshivets
 
Kshivets elcc2022
Kshivets elcc2022Kshivets elcc2022
Kshivets elcc2022
Oleg Kshivets
 
Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659
Oleg Kshivets
 
Kshivets eso10 y2021
Kshivets eso10 y2021Kshivets eso10 y2021
Kshivets eso10 y2021
Oleg Kshivets
 

More from Oleg Kshivets (11)

Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
 
Kshivets Oleg Optimization of Management for Esophageal Cancer Patients (T1-...
Kshivets Oleg  Optimization of Management for Esophageal Cancer Patients (T1-...Kshivets Oleg  Optimization of Management for Esophageal Cancer Patients (T1-...
Kshivets Oleg Optimization of Management for Esophageal Cancer Patients (T1-...
 
Kshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdfKshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdf
 
Kshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdfKshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdf
 
Kshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdfKshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdf
 
Lung Cancer: Precise Prediction
Lung Cancer: Precise PredictionLung Cancer: Precise Prediction
Lung Cancer: Precise Prediction
 
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...
 
• Gastric cancer prognosis and cell ratio factors
•	Gastric cancer prognosis and cell ratio factors           •	Gastric cancer prognosis and cell ratio factors
• Gastric cancer prognosis and cell ratio factors
 
Kshivets elcc2022
Kshivets elcc2022Kshivets elcc2022
Kshivets elcc2022
 
Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659
 
Kshivets eso10 y2021
Kshivets eso10 y2021Kshivets eso10 y2021
Kshivets eso10 y2021
 

Recently uploaded

Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdfOsteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
Jim Jacob Roy
 
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptxPost-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
FFragrant
 
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of RespirationThe Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
MedicoseAcademics
 
Histololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptxHistololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptx
AyeshaZaid1
 
Acute Gout Care & Urate Lowering Therapy .pdf
Acute Gout Care & Urate Lowering Therapy .pdfAcute Gout Care & Urate Lowering Therapy .pdf
Acute Gout Care & Urate Lowering Therapy .pdf
Jim Jacob Roy
 
vonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentationvonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentation
Dr.pavithra Anandan
 
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
19various
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
Dr. Jyothirmai Paindla
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
Tina Purnat
 
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptxMuscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
Josep Vidal-Alaball
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
rishi2789
 
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPromoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
PsychoTech Services
 
CBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdfCBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdf
suvadeepdas911
 
Cervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptxCervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptx
LEFLOT Jean-Louis
 
Outbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptxOutbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptx
Pratik328635
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
LaniyaNasrink
 
Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and AntagonistPharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
Dr. Nikhilkumar Sakle
 
Top Travel Vaccinations in Manchester
Top Travel Vaccinations in ManchesterTop Travel Vaccinations in Manchester
Top Travel Vaccinations in Manchester
NX Healthcare
 
Chapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptxChapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptx
Earlene McNair
 

Recently uploaded (20)

Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdfOsteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
 
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptxPost-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
 
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of RespirationThe Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
 
Histololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptxHistololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptx
 
Acute Gout Care & Urate Lowering Therapy .pdf
Acute Gout Care & Urate Lowering Therapy .pdfAcute Gout Care & Urate Lowering Therapy .pdf
Acute Gout Care & Urate Lowering Therapy .pdf
 
vonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentationvonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentation
 
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
 
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptxMuscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
 
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPromoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
 
CBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdfCBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdf
 
Cervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptxCervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptx
 
Outbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptxOutbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptx
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
 
Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and AntagonistPharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
 
Top Travel Vaccinations in Manchester
Top Travel Vaccinations in ManchesterTop Travel Vaccinations in Manchester
Top Travel Vaccinations in Manchester
 
Chapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptxChapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptx
 

Lung Cancer: 10-Year Survival

  • 1. elcc-congress.org LUNG CANCER: 10-YEAR SURVIVAL #358 Kshivets Oleg Surgery Department, Roshal Hospital, Moscow, Russia No disclosures e-mail: okshivets@yahoo.com
  • 2. EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021 DECLARATION OF INTERESTS Oleg Kshivets No disclosures
  • 3. EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021 LUNG CANCER: 10-YEAR SURVIVAL #358 Oleg Kshivets, MD, PhD Surgery Department, Roshal Hospital, Roshal, Moscow, Russia OBJECTIVE: 10-Year survial (10YS) after radical surgery for non-small cell lung cancer (LC) patients (LCP) (T1-4N0-2M0) was analyzed. METHODS: We analyzed data of 768 consecutive LCP (age=57.6±8.3 years; tumor size=4.1±2.4 cm) radically operated (R0) and monitored in 1985-2021 (m=660, f=108; upper lobectomies=277, lower lobectomies=177, middle lobectomies=18, bilobectomies=42, pneumonectomies=254, mediastinal lymph node dissection=768; combined procedures with resection of trachea, carina, atrium, aorta, VCS, vena azygos, pericardium, liver, diaphragm, ribs, esophagus=193; only surgery-S=618, adjuvant chemoimmunoradiotherapy-AT=150: CAV/gemzar + cisplatin + thymalin/taktivin + radiotherapy 45-50Gy; T1=320, T2=255, T3=133, T4=60; N0=516, N1=131, N2=121, M0=768; G1=194, G2=243, G3=331; squamous=417, adenocarcinoma=301, large cell=50; early LC=214, invasive LC=554; right LC=412, left LC=356; central=290; peripheral=478. Variables selected for 10YS study were input levels of 45 blood parameters, sex, age, TNMG, cell type, tumor size. Survival curves were estimated by the Kaplan-Meier method. Differences in curves between groups of LCP were evaluated using a log-rank test. Multivariate Cox modeling, discriminant analysis, clustering, SEPATH, Monte Carlo, bootstrap and neural networks computing were used to determine any significant dependence. RESULTS: Overall life span (LS) was 2244.9±1750.3 days and cumulative 5-year survival (5YS) reached 72.9%, 10 years – 64.3%, 20 yers – 43.1%. 502 LCP lived more than 5 years (LS=3128.7±1536.8 days), 145 LCP – more than 10 years (LS=5068.5±1513.2 days).199 LCP died because of LC (LS=562.7±374.5 days). AT significantly improved 10YS (52.4% vs. 27.7%) (P=0.00002 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 10YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time, weight, color index (P=0.000-0.039). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 10YS and PT early-invasive LC (rank=1), thrombocytes/CC (rank=2), PT N0—N12(rank=3), segmented neutrophils/CC (4), healthy cells/CC (5), lymphocytes/CC (6), erythrocytes/CC (7), stick neutrophils/CC (8), eosinophils/CC (9), leucocytes/CC (10), monocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0). CONCLUSIONS: 10-Year survival of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) anthropometric data; 10) surgery type; 11) tumor localization. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
  • 4. EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021 DATA: Males…………………………………….…………………………..…….660 Females…….......................................................................................108 Age=57.6±8.3 years Tumor Size=4.1±2.4 cm Only Surgery.…..................................................................................618 Adjuvant Chemoimmunoradiotherapy (CAV/gemzar + cisplatin + thymalin/taktivin, 5-6 cycles+ Radiotherapy 45-50Gy)...................150
  • 5. EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021 RADICAL PROCEDURES (R0): Upper Lobectomies …………………….………………………………...277 Lower Lobectomies ……………..........................................................177 Middle Lobectomies………………….…..………………………………..18 Bilobectomies……………………………………..…………………….…..42 Pneumonectomies…………………………………………………..…....254 Combined Procedures with Resection of Carina, Trachea, Atrium, Aorta, Liver, Vena Cava Superior, Vena Azygos, Diaphragm, Pericardium, Ribs, Esophagus (R0)…………………………………...193 Mediastinal Lymph Node Dissection.……………………………….…768
  • 6. EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021 SURVIVAL RATE: 5-Year Survivors…………......................................................502 (65.4%) 10-Year Survivors……………………………………................145 (18.9%) Losses……………………………………………………………..199 (25.9%) General Life Span=2244.9±1750.3 days For 5-Year Survivors=3128.7±1536.8 days For 10-Year Survivors=5068.5±1513.2 days For Losses=562.7±374.5 days Cumulative 5-Year Survival……..……….........................................72.9% Cumulative 10-Year Survival……..…...……………………………...64.3% Cumulative 20-Year Survival………………………………………....43.1%
  • 7. EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021 GENERAL LUNG CANCER PATIENTS SURVIVAL AFTER COMPLETE LOBECTOMIES/PNEUMONECTOMIES (KAPLAN-MEIER) (N=768): Survival Function 5-Year Survival=72.9%; 10-Year survival=64.3%; 20-Year Survival=43.1%; n=768; T1-4N0-2M0 Complete Censored -5 0 5 10 15 20 25 30 Years after Lobectomies/Pneumonectomies 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Cumulative Proportion Surviving
  • 8. EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021 RESULTS OF UNIVARIATE ANALYSIS OF PHASE TRANSITION EARLY—INVASIVE CANCER IN PREDICTION OF LUNG CANCER PATIENTS SURVIVAL (N=768): Cumulative Proportion Surviving (Kaplan-Meier) 10-Year Survival of Early Lung Cancer Patients=93.9%; 10-Year Surival of Invasive Lung Cancer Patients=51.8%; P=0.0000 by Log Rank Test Complete Censored 0 5 10 15 20 25 30 35 Years after Lobectomies/Pneumonectomies -0.2 0.0 0.2 0.4 0.6 0.8 1.0 Cumulative Proportion Surviving Invasive Lung Cancer, n=554 Early Lung Cancer, n=214
  • 9. EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021 RESULTS OF UNIVARIATE ANALYSIS OF PHASE TRANSITION N0—N1-2 IN PREDICTION OF LUNG CANCER PATIENTS SURVIVAL (N=768): Cumulative Proportion Surviving (Kaplan-Meier) 10-Year Survival of Lung Cancer Patients with N0=78.3%; 10-Year Survival of Lung Cancer Patients with N1-2=35.2%; P=0.0000 by Log Rank Test Complete Censored 0 5 10 15 20 25 30 35 Years After Lobectomies/Pneumonectomies 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Cumulative Proportion Surviving Lung Cancer with N1-2, n=252 Lung Cancer with N0=516
  • 10. EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021 RESULTS OF UNIVARIATE ANALYSIS OF ADJUVANT CHEMOIMMUNORADIOTHERAPY IN PREDICTION OF LUNG CANCER PATIENTS SURVIVAL WITH N1-2 (N=252): Cumulative Proportion Surviving (Kaplan-Meier) 10-Year Survival of LCP after AT=52.4%; 10-Year Survival of LCP after Surgery=27.7%; P=0.00002 by Log Rank Test Complete Censored 0 5 10 15 20 25 30 Years after Lobectomies/Pneumonectomies 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Cumulative Proportion Surviving Only Surgery, n=164 Adjuvant Chemoimmunoradiotherapy, n=88
  • 11. EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021 Cumulative Proportion Surviving (Kaplan-Meier) 10-Year Survival after Lobectomies=72%; 10-Year Survival after Pneumonectomies=46.9%; P=0.00002 by Log Rank Test Complete Censored 0 5 10 15 20 25 30 35 Years after Lobectomies/Pneumonectomies -0.1 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Cumulative Proportion Surviving Pneumonectomies, n=254 Lobectomies, n=514 RESULTS OF UNIVARIATE ANALYSIS OF TYPE OF PROCEDURES IN PREDICTION OF LUNG CANCER PATIENTS SURVIVAL (N=768):
  • 12. EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021 RESULTS OF UNIVARIATE ANALYSIS OF GENDER IN PREDICTION OF LUNG CANCER PATIENTS SURVIVAL (N=768): Cumulative Proportion Surviving (Kaplan-Meier) 10-Year Survival of Female LCP=73.4%; 10-Year Survival of Male LCP=63.4%; P=0.0289 by Log Rank Test Complete Censored 0 5 10 15 20 25 30 35 Years after Lobectomies/Pneumonectomies 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Cumulative Proportion Surviving male, n=660 female, n=108
  • 13. EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021 RESULTS OF COX REGRESSION MODELING IN PREDICTION OF LUNG CANCER PATIENTS SURVIVAL AFTER COMPLETE LOBECTOMIES/PNEUMONECTOMIES (N=768): Cox Proportional Hazards Results, LCP T1-4N0-2M0, n=768 Parameter Estimate Standard Error Chi-square P value Thrombocytes/Cancer Cells -0.00550 0.001579 12.14276 0.000493 Healthy Cells/Cancer Cells 0.07391 0.024958 8.77037 0.003062 Adjuvant Chemoimmunoradiotherapy -1.13036 0.201727 31.39806 0.000000 Phase Transition N0---N12 1.12121 0.144416 60.27584 0.000000 Phase Transition Early-Invasive Cancer -1.47130 0.341717 18.53830 0.000017 Histology 0.35066 0.084684 17.14621 0.000035 G1-3 0.36443 0.087580 17.31503 0.000032 Color Index -2.18363 0.917025 5.67018 0.017256 Glucose -0.32526 0.078234 17.28559 0.000032 Prothrombin Index 0.03372 0.006854 24.20847 0.000001 Bilirubin 0.05124 0.018274 7.86319 0.005045 Recalcification Time -0.00444 0.001711 6.73236 0.009468 Heparin Tolerance 0.00392 0.000662 35.06287 0.000000 Thrombocytes (tot) 0.00172 0.000341 25.43339 0.000000 Monocytes -0.05039 0.024421 4.25828 0.039059 Weight -0.03451 0.008725 15.64460 0.000076
  • 14. EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021 RESULTS OF NEURAL NETWORKS COMPUTING IN PREDICTION OF LUNG CANCER PATIENTS SURVIVAL AFTER COMPLETE LOBECTOMIES/PNEUMONECTOMIES (N=701): Neural Networks: n=701; Baseline Error=0.000; Area under ROC Curve=1.000; Correct Classification Rate=100% Rank Sensitivity Phase Transition Early--Invasive Cancer 1 11646 Thrombocytes/Cancer Cells 2 7184 Phase Transition N0--N12 Segmented Neutrophils/Cancer Cells Healthy Cells/Cancer Cells Lymphocytes/Cancer Cells Erythrocytes/Cancer Cells Stick Neutrophils/Cancer Cells Eosinophils/Cancer Cells Leucocytes/Cancer Cells Monocytes/Cancer Cells 3 4 5 6 7 8 9 10 11 6656 4154 4407 3993 3370 2963 2224 1566 1206
  • 15. EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021 RESULTS OF BOOTSTRAP SIMULATION IN PREDICTION OF LUNG CANCER PATIENTS SURVIVAL AFTER LOBECTOMIES/PNEUMONECTOMIES (N=701): Bootstrap Simulation n=701 Significant Factors (Number of Samples=3333) Rank Kendall’Tau-A P< Lymphocytes/Cancer Cells 1 0.269 0.000 Leucocytes/Cancer Cells 2 0.223 0.000 Healthy Cells/Cancer Cells 3 0.211 0.000 Erythrocytes/Cancer Cells 4 0.193 0.000 Thrombocytes/Cancer Cells 5 0.192 0.000 Lymphocytes (tot) 6 0.183 0.000 Segmented Neutrophils/Cancer Cells 7 0.173 0.000 Tumor Size 8 -0.118 0.000 Monocytes/Cancer Cells 9 0.111 0.000 PT Early---Invasive Cancer 10 0.107 0.000 Lymphocytes (%) 11 0.105 0.000 Segmented Neutrophils (%) 12 -0.102 0.000 Lymphocytes (abs) 13 0.096 0.000 Prothrombin Index 14 -0.094 0.001 T1-4 15 -0.094 0.001 PT N0---N12 16 -0.092 0.001 Procedures Type 17 0.087 0.01 Histology 18 0.076 0.01 Stick Neutrophils/Cancer Cells 19 0.073 0.01 Eosinophils/Cancer Cells 20 0.067 0.05 Age 21 -0.067 0.05 Fibrinogen 22 -0.052 0.05
  • 16. EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021 RESULTS OF KOHONEN SELF-ORGANIZING NEURAL NETWORKS COMPUTING IN PREDICTION OF LUNG CANCER PATIENTS SURVIVAL AFTER LOBECTOMIES/PNEUMONECTOMIES (N=701):
  • 17. EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021 LUNG CANCER DYNAMICS:
  • 18. EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021 PROGNOSTIC EQUATION MODELS OF LUNG CANCER PATIENTS SURVIVAL AFTER LOBECTOMIES/PNEUMONECTOMIES (N=701):
  • 19. EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021 PROGNOSTIC EQUATION MODELS OF LUNG CANCER PATIENTS SURVIVAL AFTER LOBECTOMIES/PNEUMONECTOMIES (N=701):
  • 20. EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021 PROGNOSTIC SEPATH-MODEL OF LUNG CANCER PATIENTS SURVIVAL AFTER LOBECTOMIES/PNEUMONECTOMIES (N=701):
  • 21. EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021 Conclusion: 10-Year survival of LCP after radical procedures significantly depended on: 1) phase transition early-invasive cancer; 2) phase transition N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) adjuvant chemoimmunoradiotherapy; 8) lung cancer characteristics; 9) anthropometric data; 10) surgery type; 11) tumor localization.
  • 22. EUROPEAN LUNG CANCER VIRTUAL CONGRESS 2021 Conclusion: Optimal diagnosis and treatment strategies for lung cancer are: 1) screening and early detection; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for lung cancer patients with unfavorable prognosis.
  • 23. elcc-congress.org Address: Oleg Kshivets, M.D., Ph.D. Consultant Thoracic, Abdominal, General Surgeon & Surgical Oncologist e-mail: okshivets@yahoo.com skype: okshivets http: //www.ctsnet.org/home/okshivets